Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections

References

• MarrKACarterRACrippaFWaldACoreyLEpidemiology and outcome of mould infections in hematopoietic stem cell transplant recipientsClin Infect Dis200234790991711880955
   PubMed Web of Science ®Google Scholar
• KontoyiannisDPWesselVCBodeyGPRolstonKVZygomycosis in the 1990s in a tertiary-care cancer centerClin Infect Dis200030685185610852735
   PubMed Web of Science ®Google Scholar
• MarrKAFungal infections in hematopoietic stem cell transplant recipientsMed Mycol200846429330218415836
   PubMed Web of Science ®Google Scholar
• WaldALeisenringWvan BurikJABowdenRAEpidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantationJ Infect Dis19971756145914669180187
   PubMed Web of Science ®Google Scholar
• UptonAKirbyKACarpenterPBoeckhMMarrKAInvasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortalityClin Infect Dis200744453154017243056
   PubMed Web of Science ®Google Scholar
• Garcia-VidalCUptonAKirbyKAMarrKAEpidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantationClin Infect Dis20084781041105018781877
   PubMed Web of Science ®Google Scholar
• SlavinMAOsborneBAdamsREfficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind studyJ Infect Dis19951716154515527769290
   PubMed Web of Science ®Google Scholar
• GoodmanJLWinstonDJGreenfieldRAA controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantationN Engl J Med1992326138458511542320
   PubMed Web of Science ®Google Scholar
• RexJHBennettJESugarAMA randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National InstituteN Engl J Med199433120132513307935701
   PubMed Web of Science ®Google Scholar
• LouieADrusanoGLBanerjeePPharmacodynamics of fluconazole in a murine model of systemic candidiasisAntimicrob Agents Chemother1998425110511099593135
   PubMed Web of Science ®Google Scholar
• KlepserMEMaloneDLewisREErnstEJPfallerMAEvaluation of voriconazole pharmacodynamics using time-kill methodologyAntimicrob Agents Chemother20004471917192010858354
   PubMed Web of Science ®Google Scholar
• AndesDMarchilloKConklinRPharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasisAntimicrob Agents Chemother200448113714214693531
   PubMed Web of Science ®Google Scholar
• Diflucan [Package insert]New York, NYRoerig2008
   Google Scholar
• ZimmermannTYeatesRALaufenHPfaffGWildfeuerAInfluence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazoleEur J Clin Pharmacol19944621471508039534
   PubMed Web of Science ®Google Scholar
• Sporanox [Package insert]Raritan, NJPriCara2009
   Google Scholar
• PrenticeAGWarnockDWJohnsonSAPhillipsMJOliverDAMultiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipientsJ Antimicrob Chemother19943422472527814285
   PubMed Web of Science ®Google Scholar
• LutsarIRoffeySTrokePVoriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patientsClin Infect Dis200337572873212942409
   PubMed Web of Science ®Google Scholar
• HariprasadSMMielerWFHolzERDetermination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humansArch Ophthalmol20041221424714718293
   PubMedGoogle Scholar
• Vfend [Package insert]New York, NYRoerig2008
   Google Scholar
• PurkinsLWoodNGhahramaniPGreenhalghKAllenMJKleinermansDPharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimensAntimicrob Agents Chemother20024682546255312121931
   PubMed Web of Science ®Google Scholar
• Noxafil [Package insert]Kenilworth, NJSchering-Plough2008
   Google Scholar
• CourtneyRWexlerDRadwanskiELimJLaughlinMEffect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adultsBr J Clin Pharmacol200457221822214748822
   PubMed Web of Science ®Google Scholar
• EzzetFWexlerDCourtneyRKrishnaGLimJLaughlinMOral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendationsClin Pharmacokinet200544221122015656699
   PubMed Web of Science ®Google Scholar
• UllmannAJCornelyOABurchardtAPharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infectionAntimicrob Agents Chemother200650265866616436724
   PubMed Web of Science ®Google Scholar
• RupingMJAlbermannNEbingerFPosaconazole concentrations in the central nervous systemJ Antimicrob Chemother20086261468147018824458
   PubMed Web of Science ®Google Scholar
• ReinwaldMUharekLLampeDGroboschTThielESchwartzSLimited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosisBone Marrow Transplant200944426927019219077
   PubMed Web of Science ®Google Scholar
• HornDNeofytosDFishmanJUse of the PATH alliance database to measure adherence to IDSA guidelines for the therapy of candidemiaEur J Clin Microbiol Infect Dis2007261290791417899230
   PubMed Web of Science ®Google Scholar
• GareyKWRegeMPaiMPTime to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multiinstitutional studyClin Infect Dis2006431253116758414
   PubMed Web of Science ®Google Scholar
• WalshTJAnaissieEJDenningDWTreatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of AmericaClin Infect Dis200846332736018177225
   PubMed Web of Science ®Google Scholar
• PappasPGKauffmanCAAndesDClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of AmericaClin Infect Dis200948550353519191635
   PubMed Web of Science ®Google Scholar
• OlyaeiA Focus in Fungal Infections, 19 meeting: An analysis of antifungal dosing patterns from a cohort of more than 6900 patients at 74 North American centers (2004–2008); March 4–6, 2009, Fort Myers, FL.
   Google Scholar
• MizutaniTPM frequencies of major CYPs in Asians and CaucasiansDrug Metab Rev2003352–39910612959412
   PubMed Web of Science ®Google Scholar
• WeissJTen HoevelMMBurhenneJCYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazoleJ Clin Pharmacol200949219620419033450
   PubMed Web of Science ®Google Scholar
• ZoniosDIBennettJEUpdate on azole antifungalsSemin Respir Crit Care Med200829219821018366001
   PubMed Web of Science ®Google Scholar
• CohenLGDiBiasioALiscoSJHurfordWEFluconazole serum concentrations and pharmacokinetics in an obese patientPharmacotherapy1997175102310269324192
   PubMed Web of Science ®Google Scholar
• LangeDPavaoJHWuJKlausnerMEffect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockersJ Clin Pharmacol19973765355409208361
   PubMed Web of Science ®Google Scholar
• ZimmermannTYeatesRAAlbrechtMLaufenHWildfeuerAInfluence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjectsInt J Clin Pharmacol Res199414387937883389
   PubMedGoogle Scholar
• BaroneJAMoskovitzBLGuarnieriJFood interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteersPharmacotherapy19981822953019545149
   PubMed Web of Science ®Google Scholar
• PascualACalandraTBolaySBuclinTBilleJMarchettiOVoriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomesClin Infect Dis200846220121118171251
   PubMed Web of Science ®Google Scholar
• CourtneyRRadwanskiELimJLaughlinMPharmacokinetics of posaconazole coadministered with antacid in fasting or non-fasting healthy menAntimicrob Agents Chemother200448380480814982768
   PubMed Web of Science ®Google Scholar
• Sansone-ParsonsAKrishnaGCalzettaAEffect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteersAntimicrob Agents Chemother20065051881188316641468
   PubMed Web of Science ®Google Scholar
• KosoglouTPerentesisGPAffrimeMBThe effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304J Clin Pharmacol19903076386422391395
   PubMed Web of Science ®Google Scholar
• JainRPottingerPThe effect of gastric acid on the absorption of posaconazoleClin Infect Dis200846101627 author reply 1627–162818419503
   PubMed Web of Science ®Google Scholar
• AlffenaarJWvan AssenSvan der WerfTSKosterinkJGUgesDROmeprazole significantly reduces posaconazole serum trough levelClin Infect Dis200948683919220151
   PubMed Web of Science ®Google Scholar
• UllmannAJLiptonJHVesoleDHPosaconazole or fluconazole for prophylaxis in severe graft-versus-host diseaseN Engl J Med2007356433534717251530
   PubMed Web of Science ®Google Scholar
• KrishnaGMartinhoMChandrasekarPUllmannAJPatinoHPharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host diseasePharmacotherapy200727121627163618041883
   PubMed Web of Science ®Google Scholar
• KrishnaGAbuTarifMXuanFMartinhoMAnguloDCornelyOAPharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndromePharmacotherapy200828101223123218823218
   PubMed Web of Science ®Google Scholar
• NicolauDPCroweHNightingaleCHQuintilianiRBioavailability of fluconazole administered via a feeding tube in intensive care unit patientsJ Antimicrob Chemother19953623954018522469
   PubMed Web of Science ®Google Scholar
• OngDLFobesLMAdministering itraconazole via nasogastric tubeAm J Health Syst Pharm1996531619628862212
   PubMed Web of Science ®Google Scholar
• MartinezVLe GuillouJLLamerCLe JouanMTodMDromerFSerum voriconazole levels following administration via percutaneous jejunostomy tubeAntimicrob Agents Chemother20034710337514506064
   PubMed Web of Science ®Google Scholar
• GrauSMateu-DeAJAlvarez-LermaFMarin-CasinoMTorres-RodriguezJMSuccessful treatment of an aspergillus fumigatus infection with voriconazole via a nasogastric tubeJ Chemother200618444544617024806
   PubMed Web of Science ®Google Scholar
• Dodds AshleyESVarkeyJBKrishnaGPharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteersAntimicrob Agents Chemother20095372960296419433558
   PubMed Web of Science ®Google Scholar
• BergeMGuillemainRBoussaudVVoriconazole pharmacokinetic variability in cystic fibrosis lung transplant patientsTranspl Infect Dis200911321121919302272
   PubMed Web of Science ®Google Scholar
• LeeBEFeinbergMAbrahamJJMurthyARCongenital malformations in an infant born to a woman treated with fluconazolePediatr Infect Dis J19921112106210641461702
   PubMed Web of Science ®Google Scholar
• PursleyTJBlomquistIKAbrahamJAndersenHFBartleyJAFluconazole-induced congenital anomalies in three infantsClin Infect Dis19962223363408838193
   PubMed Web of Science ®Google Scholar
• SorensenHTNielsenGLOlesenCRisk of malformations and other outcomes in children exposed to fluconazole in uteroBr J Clin Pharmacol199948223423810417502
   PubMed Web of Science ®Google Scholar
• NorgaardMPedersenLGislumMMaternal use of fluconazole and risk of congenital malformations: A Danish population-based cohort studyJ Antimicrob Chemother200862117217618400803
   PubMed Web of Science ®Google Scholar
• TiboniGMSecond branchial arch anomalies induced by fluconazole, a bistriazole antifungal agent, in cultured mouse embryosRes Commun Chem Pathol Pharmacol19937933813848480084
   PubMedGoogle Scholar
• Bar-OzBMorettiMEBishaiRPregnancy outcome after in utero exposure to itraconazole: A prospective cohort studyAm J Obstet Gynecol2000183361762010992182
   PubMed Web of Science ®Google Scholar
• De SantisMDi GianantonioECesariEAmbrosiniGStrafaceGClementiMFirst-trimester itraconazole exposure and pregnancy outcome: A prospective cohort study of women contacting teratology information services in ItalyDrug Saf200932323924419338381
   PubMed Web of Science ®Google Scholar
• SaadAHDePestelDDCarverPLFactors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressantsPharmacotherapy200626121730174417125435
   PubMed Web of Science ®Google Scholar
• PappasPGKauffmanCAPerfectJAlopecia associated with fluconazole therapyAnn Intern Med199512353543577625624
   PubMed Web of Science ®Google Scholar
• AhmadSRSingerSJLeissaBGCongestive heart failure associated with itraconazoleLancet200135792701766176711403818
   PubMed Web of Science ®Google Scholar
• SharkeyPKRinaldiMGDunnJFHardinTCFetchickRJGraybillJRHigh-dose itraconazole in the treatment of severe mycosesAntimicrob Agents Chemother19913547077131648887
   PubMed Web of Science ®Google Scholar
• AllyRSchurmannDKreiselWA randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patientsClin Infect Dis20013391447145411577374
   PubMed Web of Science ®Google Scholar
• Ostrosky-ZeichnerLOude LashofAMKullbergBJRexJHVoriconazole salvage treatment of invasive candidiasisEur J Clin Microbiol Infect Dis2003221165165514564539
   PubMed Web of Science ®Google Scholar
• SambatakouHDupontBLodeHDenningDWVoriconazole treatment for subacute invasive and chronic pulmonary aspergillosisAm J Med20061196527e17e2416750972
   PubMed Web of Science ®Google Scholar
• WalshTJPappasPWinstonDJVoriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent feverN Engl J Med2002346422523411807146
   PubMed Web of Science ®Google Scholar
• KullbergBJSobelJDRuhnkeMVoriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trialLancet200536694951435144216243088
   PubMed Web of Science ®Google Scholar
• HerbrechtRDenningDWPattersonTFVoriconazole versus amphotericin B for primary therapy of invasive aspergillosisN Engl J Med2002347640841512167683
   PubMed Web of Science ®Google Scholar
• DenningDWRibaudPMilpiedNEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosisClin Infect Dis200234556357111807679
   PubMed Web of Science ®Google Scholar
• DenningDWGriffithsCEMuco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazoleClin Exp Dermatol200126864865311722447
   PubMed Web of Science ®Google Scholar
• TanKBrayshawNTomaszewskiKTrokePWoodNInvestigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalitiesJ Clin Pharmacol200646223524316432276
   PubMed Web of Science ®Google Scholar
• ZoniosDIGea-BanaclocheJChildsRBennettJEHallucinations during voriconazole therapyClin Infect Dis2008471e7e1018491963
   PubMed Web of Science ®Google Scholar
• ImhofASchaerDJSchanzUSchwarzUNeurological adverse events to voriconazole: Evidence for therapeutic drug monitoringSwiss Med Wkly200613645–4673974217183438
   PubMed Web of Science ®Google Scholar
• AllyRSchurmannDKreiselWA randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patientsClin Infect Dis20013391447145411577374
   PubMed Web of Science ®Google Scholar
• Ostrosky-ZeichnerLOude LashofAMKullbergBJRexJHVoriconazole salvage treatment of invasive candidiasisEur J Clin Microbiol Infect Dis2003221165165514564539
   PubMed Web of Science ®Google Scholar
• RubensteinMLevyMLMetryDVoriconazole-induced retinoid-like photosensitivity in childrenPediatr Dermatol200421667567815575856
   PubMed Web of Science ®Google Scholar
• VandecasteeleSJVan WijngaerdenEPeetermansWETwo cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazoleEur J Clin Microbiol Infect Dis200423865665715248093
   PubMed Web of Science ®Google Scholar
• DolanCKHallMABlazesDLNorwoodCWPseudoporphyria as a result of voriconazole use: A case reportInt J Dermatol2004431076877115485539
   PubMed Web of Science ®Google Scholar
• RacetteAJRoenigkHHJrHansenRMendelsonDParkAPhotoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girlJ Am Acad Dermatol2005525 Suppl 1S81S8515858516
   PubMed Web of Science ®Google Scholar
• TollandJPMcKeownPPCorbettJRVoriconazole-induced pseudoporphyriaPhotodermatol Photoimmunol Photomed2007231293117254033
   PubMed Web of Science ®Google Scholar
• KwongWTHsuSPseudoporphyria associated with voriconazoleJ Drugs Dermatol20076101042104417966183
   PubMedGoogle Scholar
• McCarthyKLPlayfordEGLookeDFWhitbyMSevere photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapyClin Infect Dis2007445e55e5617278050
   PubMed Web of Science ®Google Scholar
• MalaniANAronoffDMVoriconazole-induced photosensitivityClin Med Res200862838518801950
   PubMedGoogle Scholar
• AlexanderBDPerfectJRDalyJSPosaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplantTransplantation200886679179618813103
   PubMed Web of Science ®Google Scholar
• HachemRYLangstonAAGraybillJRPosaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairmentJ Antimicrob Chemother20086261386139118835806
   PubMed Web of Science ®Google Scholar
• WalshTJRaadIPattersonTFTreatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trialClin Infect Dis200744121217143808
   PubMed Web of Science ®Google Scholar
• HardinTCGraybillJRFetchickRWoestenborghsRRinaldiMGKuhnJGPharmacokinetics of itraconazole following oral administration to normal volunteersAntimicrob Agents Chemother1988329131013132848442
   PubMed Web of Science ®Google Scholar
• WheatLJFreifeldAGKleimanMBClinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of AmericaClin Infect Dis200745780782517806045
   PubMed Web of Science ®Google Scholar
• HopeWWBillaudEMLestnerJDenningDWTherapeutic drug monitoring for triazolesCurr Opin Infect Dis200821658058618978525
   PubMed Web of Science ®Google Scholar
• HowardAHoffmanJShethAClinical application of voriconazole concentrations in the treatment of invasive aspergillosisAnn Pharmacother200842121859186419017830
   PubMed Web of Science ®Google Scholar
• TrifilioSPennickGPiJMonitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipientsCancer200710981532153517351937
   PubMed Web of Science ®Google Scholar
• TrifilioSSinghalSWilliamsSBreakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazoleBone Marrow Transplant200740545145617589527
   PubMed Web of Science ®Google Scholar
• TrifilioSOrtizRPennickGVoriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipientsBone Marrow Transplant200535550951315654347
   PubMed Web of Science ®Google Scholar
• BadenLRKatzJTFishmanJASalvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapyTransplantation200376111632163714702539
   PubMed Web of Science ®Google Scholar
• MotonAKrishnaGWangZTolerability and safety profile of posaconazole: Evaluation of 18 controlled studies in healthy volunteersJ Clin Pharm Ther200934330131119646076
   PubMed Web of Science ®Google Scholar
• RaadIIHannaHABoktourMNovel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: Posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofunginLeukemia200822349650318094720
   PubMed Web of Science ®Google Scholar
• CornelyOAMaertensJWinstonDJPosaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropeniaN Engl J Med2007356434835917251531
   PubMed Web of Science ®Google Scholar
• RaadIIGraybillJRBustamanteABSafety of long-term oral posaconazole use in the treatment of refractory invasive fungal infectionsClin Infect Dis200642121726173416705579
   PubMed Web of Science ®Google Scholar
• RaadIIHachemRYHerbrechtRPosaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditionsClin Infect Dis200642101398140316619151
   PubMed Web of Science ®Google Scholar